Cytokinetics (CYTK) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $62.33 --0%
Revenue Growth %: +2,004.1%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
RCBC, SSL, PFBC, More
Revenue Growth %: +2,004.1%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
RCBC, SSL, PFBC, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Upgrades ABB Ltd (ABB) to Outperform
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
- Farmers & Merchants Bancorp, Inc. (FMAO) Tops Q3 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
